Vizimpro Side Effects

Generic name: dacomitinib

Medically reviewed by Drugs.com. Last updated on Oct 14, 2023.

Note: This document contains side effect information about dacomitinib. Some dosage forms listed on this page may not apply to the brand name Vizimpro.

Applies to dacomitinib: oral tablet.

Serious side effects of Vizimpro

Along with its needed effects, dacomitinib (the active ingredient contained in Vizimpro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dacomitinib:

More common

Blistering, crusting, irritation, itching, or reddening of the skin
body aches or pain
chest pain
chills
cough
cracked lips
cracked, dry, or scaly skin
deep cracks, grooves, or lines in the skin
diarrhea
difficulty in swallowing
ear congestion
fever
headache
itching, skin rash
loosening of the fingernails
loss of voice
nasal congestion
redness or soreness around the fingernails
redness, swelling, or pain of the skin
runny nose
scaling of the skin on the hands and feet
sneezing
sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth
swelling
tightness in the chest
tingling of the hands and feet
trouble breathing
ulceration of the skin
unusual tiredness or weakness

Less common

Confusion
decreased urination
dizziness
dry mouth
fainting
fever
increase in heart rate
lightheadedness
loss of heat from the body
rapid breathing
sunken eyes
thirst
wrinkled skin

Other side effects of Vizimpro

Some side effects of dacomitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Burning, dry, or itching eyes
change in taste
constipation
decreased appetite
decreased weight
discharge, excessive tearing
hair loss or thinning of hair
increased hair growth on the forehead, back, arms, and legs
lack or loss of strength
loss of taste
nausea
redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
trouble sleeping
vomiting

Less common

Eye redness, irritation, or pain

For Healthcare Professionals

Applies to dacomitinib: oral tablet.

Hematologic

Very common (10% or more): Anemia (44%), hypoalbuminemia (44%), lymphopenia (42%)^[Ref]

Musculoskeletal

Very common (10% or more): Pain in extremity (14%), musculoskeletal pain (12%)^[Ref]

Ocular

Very common (10% or more): Conjunctivitis (19%)

Common (1% to 10%): Keratitis^[Ref]

Metabolic

Very common (10% or more): Hyperglycemia (36%), hypocalcemia (33%), decreased appetite (31%), decreased weight (26%), hyponatremia (26%), alkaline phosphatase increased (22%), hypomagnesemia (22%)

Common (1% to 10%): Dehydration^[Ref]

Psychiatric

Very common (10% or more): Insomnia (11%)^[Ref]

Hepatic

Very common (10% or more): ALT increased (40%), AST increased (35%), hyperbilirubinemia (16%)^[Ref]

Respiratory

Very common (10% or more): Cough (21%), nasal mucosal disorder (i.e., epistaxis, nasal inflammation, nasal mucosal ulcer, rhinitis) (19%), dyspnea (13%), upper respiratory tract infection (12%), chest pain (10%)^[Ref]

Other

Very common (10% or more): Asthenia (13%)

Common (1% to 10%): Fatigue^[Ref]

General

The most common (greater than 20%) adverse reactions were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%).^[Ref]

Nervous system

Common (1% to 10%): Dysgeusia^[Ref]

Renal

Very common (10% or more): Creatinine increased (24%)^[Ref]

Dermatologic

Very common (10% or more): Rash (i.e., dermatitis acneiform, rash, rash maculopapular)/exfoliative skin reactions (78%), paronychia (i.e., nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis) (64%), dry skin (i.e., xerosis) (30%), alopecia (30%), pruritus (21%), palmar-plantar erythrodysesthesia syndrome (15%), dermatitis (11%)^[Ref]